Synergistic Effect of Q203 Combined with PBTZ169 against Mycobacterium tuberculosis
Thanh Quang Nguyen, Bui Thi Bich Hanh, Seunghyeon Jeon, Bo Eun Heo, Yujin Park, Arunima Choudhary, Chéol Moon, Jichan Jang
Abstract
Q203 is a first-in-class drug candidate against Mycobacterium tuberculosis . In its recently completed phase 2 clinical trial, Q203 reduced the number of live M. tuberculosis cells in a dose-dependent manner.
Topics & Concepts
ResazurinMycobacterium tuberculosisIsoniazidRifampicinStreptomycinTuberculosisMicrobiologyBedaquilinePharmacologyChemistryMycobacterium marinumIn vivoBiologyAntibioticsMedicineBiotechnologyPathologyTuberculosis Research and EpidemiologyMycobacterium research and diagnosisCancer therapeutics and mechanisms